Favipiravir

Generic Name
Favipiravir
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C5H4FN3O2
CAS Number
259793-96-9
Unique Ingredient Identifier
EW5GL2X7E0
Background

Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. The antiviral targets RNA-dependent RNA polymerase (RdRp) enzymes, which are necessary for the transcription and replication of viral genomes.
...

Indication

⑴用于埃博拉病毒感染的治疗。

⑵用于治疗成人新型或再次流行的流感(仅限于其他抗流感病毒药物治疗无效或效果不佳时使用)

Associated Conditions
Treatment resistant Novel Influenza, Treatment resistant Reemerging Influenza
Associated Therapies
-

Favipiravir Therapy in Adults With Mild COVID-19

Phase 2
Completed
Conditions
Interventions
First Posted Date
2020-07-09
Last Posted Date
2021-11-05
Lead Sponsor
King Abdullah International Medical Research Center
Target Recruit Count
231
Registration Number
NCT04464408
Locations
🇸🇦

Prince Mohammed Bin Abdul Aziz Hospital - Al Madinah, Al Madinah, Saudi Arabia

🇸🇦

King Abdulaziz Medical City - Riyadh, Riyadh, Saudi Arabia

🇸🇦

Primary Health Care-Al Mansoura, Riyadh, Saudi Arabia

and more 4 locations

Control of COVID-19 Outbreaks in Long Term Care

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2020-06-25
Last Posted Date
2023-02-21
Lead Sponsor
Appili Therapeutics Inc.
Target Recruit Count
67
Registration Number
NCT04448119
Locations
🇨🇦

Mount Sinai Hospital, Toronto, Ontario, Canada

An Adaptive Clinical Trial of Antivirals for COVID-19 Infection

Phase 2
Conditions
Interventions
First Posted Date
2020-06-24
Last Posted Date
2021-10-07
Lead Sponsor
Bayside Health
Target Recruit Count
190
Registration Number
NCT04445467
Locations
🇦🇺

Alfred Health, Melbourne, Victoria, Australia

An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19

First Posted Date
2020-06-16
Last Posted Date
2020-06-16
Lead Sponsor
Chromis LLC
Target Recruit Count
330
Registration Number
NCT04434248
Locations
🇷🇺

Yakutsk City Clinical Hospital, Yakutsk, Russian Federation

🇷🇺

Moscow State University n.a. M. V. Lomonosov, Moscow, Russian Federation

🇷🇺

Infectious clinical hospital No.2 of Nizhny Novgorod, Nizhny Novgorod, Russian Federation

and more 19 locations

A Multi-center,Randomized,Double-blind,Placebo-controlled,Phase 3 Study Evaluating Favipiravir in Treatment of COVID19

Phase 3
Conditions
Interventions
First Posted Date
2020-06-11
Last Posted Date
2020-06-11
Lead Sponsor
Zhejiang Hisun Pharmaceutical Co. Ltd.
Target Recruit Count
256
Registration Number
NCT04425460
Locations
🇷🇴

"Dr.Victor Babes" Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timişoara, Timis, Romania

🇷🇴

Dr.Victor Babes Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timişoara, Timis, Romania

🇷🇴

Emergency County Hospital "Pius Brinzeu"Timisoara, Timişoara, Timis, Romania

and more 6 locations

Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh

First Posted Date
2020-05-26
Last Posted Date
2020-05-26
Lead Sponsor
Bangladesh Medical Research Council (BMRC)
Target Recruit Count
50
Registration Number
NCT04402203
Locations
🇧🇩

Mahanagar General Hospital, Dhaka (Site-1), Mugda Medical College Hospital, Dhaka (Site-2), Kurmitola General Hospital, Dhaka (Site-3), Dhaka Medical College Hospital, Dhaka (Site-4), Dhaka, Bangladesh

Favipiravir vs Hydroxychloroquine vs Control in COVID -19

First Posted Date
2020-05-14
Last Posted Date
2021-10-26
Lead Sponsor
Royal College of Surgeons in Ireland - Medical University of Bahrain
Target Recruit Count
150
Registration Number
NCT04387760
Locations
🇧🇭

Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain

Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19

First Posted Date
2020-05-06
Last Posted Date
2020-06-16
Lead Sponsor
Baqiyatallah Medical Sciences University
Target Recruit Count
40
Registration Number
NCT04376814
Locations
🇮🇷

Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of

Early Intervention in COVID-19: Favipiravir Verses Standard Care

First Posted Date
2020-05-04
Last Posted Date
2021-11-18
Lead Sponsor
Chelsea and Westminster NHS Foundation Trust
Target Recruit Count
502
Registration Number
NCT04373733
Locations
🇧🇷

Grupo Hospitalar Conceição, Porto Alegre, Brazil

🇲🇽

Instituto Nacional de Ciencias Medicas y Nutricion, Salvador Zubiran, Mexico City, Mexico

🇬🇧

Hull University Teaching Hospitals NHS Trust - Castle Hill Hospital, Hull, United Kingdom

and more 3 locations

Favipiravir in Hospitalized COVID-19 Patients

First Posted Date
2020-04-24
Last Posted Date
2020-04-28
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Target Recruit Count
40
Registration Number
NCT04359615
Locations
🇮🇷

Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of

© Copyright 2024. All Rights Reserved by MedPath